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Objective To evaluate the in vitro spectrum and activity of linezolid, a recent oxazoli-
dinone, according to well-controlled surveillance data from 42 medical centers in 13
countries throughout Europe.
Methods Participants tested the susceptibility of 125 clinical strains of enterococcal and
staphylococcal species against 13 drugs using reference broth microdilution trays or the
standardized disk diffusion method of the National Committee for Clinical Laboratory
Standards (NCCLS). Streptococcal species (n¼ 25 at each center) were tested against six
drugs using E test (AB BIODISK, Solna, Sweden). Quality assurance testing was con-
ducted usingNCCLS-recommended strains and veriﬁcation of resistance to linezolid and
other selected agents was performed by retesting strains at the regional (Europe) and
international (USA) monitor sites.
Results A total of 5598 strains from throughout Europe (91% compliance) were tested.
Vancomycin resistance was reported in only 0.6 and 3.0% of Enterococcus faecalis and E.
faecium, respectively. Penicillin resistance occurred in 25.1% of Streptococcus pneumoniae;
4.9% at the high-level (2mg/L). The MIC90 for linezolid was 1mg/L for streptococci
and 2mg/L for enterococci and staphylococci. Using the US FDA- and EUCAST-
recommended susceptible breakpoints for linezolid, there were no conﬁrmed reports
of linezolid resistance [minimum inhibitory concentration (MIC), 8mg/L]. The dis-
tribution of linezolid MIC values was unimodal and varied between 0.25 and 1mg/L for
streptococci (>90% of isolates), and between 1 and 2mg/L for staphylococci (>90%) and
enterococci (>95%). There were no differences in linezolid susceptibility in the vanco-
mycin-, oxacillin-, or penicillin-resistant subsets of strains when compared to susceptible
organism populations.
Conclusions Compared to the North American component of this study, there was
substantially less vancomycin resistance among E. faecium isolates (Europe 3.0% vs.
North America 63.4%). While the occurrence of penicillin-resistant S. pneumoniae in
Europe and North America was similar (25.1% vs. 29.7%), the recovery of high-level
penicillin-resistant strains was nearly three-fold higher in North America (4.9% vs.
13.2%). Only linezolid was universally active against all the tested Gram-positive isolates
at 4mg/L.
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INTRODUCTION
Gram-positive bacteria, both fastidious and non-
fastidious species, continue to proliferate as signi-
ﬁcant pathogens in community-acquired infections
and as formidable pathogens in hospitals where
antimicrobial resistance rates can be alarmingly
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elevated [1,2]. As resistance in major species
of staphylococci, enterococci and streptococci
continues to escalate, limiting available therapeu-
tic options, the development and introduction
of new classes of drugs are a welcome strategy
[3]. Indeed, the pharmaceutical industry has in
recent years brought to market several new com-
pounds, such as linezolid, quinupristin/dalfo-
pristin and newer quinolones with more potent
Gram-positive activity, to meet clinical needs
[4–6], and yet others have been studied extensively
in vitro [7].
Linezolid, in particular, has signiﬁcant potential
for addressing multidrug-resistance challenges
since it belongs to a totally new class, the oxazo-
lidinones [4,8,9]. Unique in its structure and mode
of action [10], linezolid has a wide spectrum of
activity encompassing staphylococci, enterococci
and streptococci (including Streptococcus pneumo-
niae), regardless of the organism’s resistance phe-
notype to other classes of antimicrobials [4,8,9,11–
15]. To promote the rational use of antimicrobial
agents, both in the introduction of a recent com-
pound such as linezolid, and for its subsequent
widespread clinical implementation, it is desirable
to document the baseline of spectrum and potency
on a global level [6,7,16–18]. This would make
postmarketing surveillance efforts both more
accurate and more meaningful, and allow for use-
ful intervention strategies to be considered in an
attempt to prolong the clinical utility of the new
class.
Although numerous surveillance programes are
reported each year [19], few provide longitudinal,
well-standardized data with internal and exter-
nal quality assurance as an integral part of the
investigation [20–23]. This study comprises the
European component of the international sur-
veillance, Zyvox1 Antimicrobial Potency Study
(ZAPS) [17], in which 42 medical centers from
13 countries throughout Europe participated in
an in vitro assessment of the comparative activity
of linezolid relative to other agents with anti-
Gram-positive spectrum of activity. A representa-
tive sample of clinically signiﬁcant aerobic and
facultatively anaerobic Gram-positive bacteria iso-
lated from wounds, abdominal cavity, respiratory
tract, blood and cerebrospinal ﬂuid specimens are
tested for their susceptibility against predeter-
mined antibiograms using well-standardized
reagents provided by the study co-ordinators.
The objective of the study is to generate an accu-
rate baseline of the current level of bacterial sus-
ceptibility to linezolid and to investigate the
emergence of speciﬁc resistances in Europe such
as vancomycin-resistant enterococci (VRE) [23],
glycopeptide-intermediate Staphylococcus aureus
(GISA) [15,24] and drug-resistant S. pneumoniae
(DRSP) [5,14,22,25,26].
MATERIALS AND METHODS
Participants
A total of 42 European investigators from 13 coun-
tries contributed isolates to this study, including
medical centers in Austria (three sites), Belgium
(two sites), Denmark (two sites), France (six sites),
Germany (ﬁve sites), Iceland (one site), Ireland
(one site), Italy (four sites), the Netherlands (two
sites), Spain (six sites), Sweden (three sites), Swit-
zerland (three sites), and the UK (four sites). Each
site was asked to test 150 isolates which were to be
divided among a deﬁned number of staphylococci,
enterococci and streptococci. The protocol design
yielded a signiﬁcant number of evaluable strains
from throughout Europe (91% compliance).
Deﬁned resistance criteria for strains of staphylo-
cocci and enterococci based on zone diameter or
minimum inhibitory concentration (MIC) values,
respectively, of linezolid (20mm or >4mg/L),
vancomycin (14mm or 4mg/L), quinupristin/
dalfopristin (18mmor2mg/L) and teicoplanin
(10mm or 32mg/L) were used to indicate the
necessity of forwarding to a central laboratory for
further testing [27]. Streptococcal MIC referral
criteria were designated as follows: linezolid
(>4mg/L), trovaﬂoxacin (>1mg/L) and quinu-
pristin/dalfopristin (>1mg/L) [27]. Isolates meet-
ing these criteria were to be referred to the regional
co-ordinator (AB BIODISK, Solna, Sweden) for
conﬁrmation. Conﬁrmed strains were then to be
sent to the international microbiology co-ordinator
(IA, USA) for further analyses, including identiﬁ-
cation veriﬁcation, repeat MIC and/or disk diffu-
sion testing [28,29] and determination of resistance
mechanisms, if needed.
Bacterial isolate collection
The activity and spectrum of linezolid and com-
parative Gram-positive and broad-spectrum anti-
microbial agents were evaluated against 5598
bacterial isolates. These strains were clinically sig-
niﬁcant isolates from a variety of patient infections
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with only one species per patient included during
the study period (1999–2000). Three species
groups (150 total strains/site) were to be tested
locally according to protocol design including S.
aureus (50 strains), coagulase-negative staphylo-
cocci (CoNS; 35 strains), enterococci (40 strains)
and streptococci (25 strains). The collected data
were sent to the regional co-ordinator and the
monitors in the United States (IA and NY, USA),
the latter of which entered and computer-pro-
cessed all the data. Identiﬁcation to species level
was performed using Vitek (bioMerieux, St. Louis,
MO) and/or routine biochemical tests.
Among the tested organisms, a total of 1950
isolates of S. aureus were included in the study,
of which 691 strains were oxacillin-resistant. CoNS
species included 836 oxacillin-resistant strains.
The Enterococcus spp. collection was dominated
by E. faecalis (815 strains) and E. faecium (262
strains), and only nine conﬁrmed vancomycin-
resistant (VRE) strains were detected. The remain-
ing streptococcal isolates included 699 strains of
S. pneumoniae and 174 strains of viridans group or
b-haemolytic streptococci, which were combined
for analysis purposes as the susceptibility among
these last two groups did not signiﬁcantly vary
among the tested compounds. Quality control
(QC) organisms included American Type Culture
Collection (ATCC) strains appropriate for testing
each genus group [27–29]. Those strains included
S. aureus ATCC 25923 and 29213 and E. faecalis
ATCC 29212. Data from sites with numerous aber-
rant QC results were not included in the ﬁnal
analyses [17].
Susceptibility testing methods
Participants used either disk diffusion or broth
microdilutionmethods (Belgium and France, only)
for non-fastidious Gram-positive pathogens
[28,29], and the E test methodology (AB BIODISK,
Solna, Sweden) when testing streptococcal species
[30]. Common E test and disk lots were used
throughout the study. Thirteen antimicrobial
agents were evaluated against the non-fastidious
isolates on Mueller–Hinton agar plates and
included Gram-positive focused compounds such
as linezolid, macrolides, clindamycin, a strepto-
gramin, chloramphenicol, doxycycline and high-
level gentamicin (Enterococcus spp. only) as well
as broader spectrum agents including various
b-lactams, glycopeptides and trovaﬂoxacin. Com-
pounds which included linezolid, quinupristin/
dalfopristin, penicillin, erythromycin, ceftriaxone
and trovaﬂoxacin were tested against the strepto-
coccal isolates on Mueller–Hinton agar supple-
mented with 5% sheep blood. All methods and
interpretative criteria complied with NCCLS [27]
and/or the manufacturer’s recommendations, not
those published by EUCAST [31].
RESULTS
Linezolid tested against staphylococci
Table 1 shows the comparative potency and spec-
trum for linezolid and 12 other agents tested
against nearly 2000 S. aureus. Using reference-
quality broth microdilution or NCCLS standar-
dized disk diffusion methods [27–30], essentially
identical and near complete spectra were observed
for linezolid (MIC90, 2mg/L; 100.0% susceptible),
vancomycin (MIC90, 1mg/L; 99.6–100.0% suscep-
tible), teicoplanin (MIC90, 0.5–2mg/L; 95.8–
100.0% susceptible), and quinupristin/dalfopris-
tin (MIC90, 0.5mg/L; 98.6–99.9% susceptible).
When non-susceptible strains (intermediate) for
the glycopeptides were detected, they were
observed using the disk diffusion test and not
conﬁrmed by the monitors. Quinupristin/dalfo-
pristin-resistant S. aureus isolates were detected by
both methods and were conﬁrmed in isolates from
France (three strains) and Denmark (one strain).
Macrolides and clindamycin were 68.3–95.2%
effective in vitro against oxacillin-susceptible
(OS) strains, but against oxacillin-resistant (OR)
strains of S. aureus in vitro susceptibility dropped
to 42.1%. Chloramphenicol and doxycycline
retained moderate potency and spectra against
OR isolates (91.8–94.3% and 83.3–85.7%, respec-
tively). Trovaﬂoxacin demonstrated only a 0.4–
1.1% non-susceptible rate for OS S. aureus, but
signiﬁcantly reduced spectra (59.3–81.5%) against
OR isolates. Among the tested b-lactams, penicil-
lins (ampicillin) were not active and the cephalos-
porins had clinical utility against OS S. aureus
(96.1–99.7%), but no activity against OR strains.
Occasional dramatic differences in the spectrum
of activity were observed between the two in vitro
methods. These were associated with the nation-
to-nation variations in staphylococcal resistance
rates to the tested ﬂuoroquinolone and macrolides
(highest in Belgium, France and Germany; gener-
ally participants using the broth microdilution
test).
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Table 2 lists the activity and spectrum of line-
zolid and 12 other drugs tested against CoNS
strains, indexed by their oxacillin susceptibility
patterns. Linezolid was equally active (MIC90,
2mg/L; 100.0% susceptible) against both groups.
Rarely, strains showed non-susceptible zone dia-
meters for vancomycin (0.3%). Teicoplanin was
slightly less active than vancomycin, especially
by the disk diffusion method when tested against
both OS- or OR-CoNS (93.2–94.7% susceptible).
CoNS isolates with resistance to the streptogramin
combination ranged from nil (OS-CoNS by broth
microdilution) to 3.8% (OR-CoNS by the same
method). The two nations reporting these isolates
were France (seven strains) and Italy (two strains).
The OR-CoNS isolates were generally less sus-
ceptible compared to OS-CoNS for the remaining
eight tested compounds. Examples of the most
dramatic changes in susceptibility were the
decreases for erythromycin (from 37.3 to 39.6%
depending on method), clindamycin (from 31.6
to 36.6%) and trovaﬂoxacin (from 12.5 to 36.6%).
Linezolid tested against Enterococcus species
The potency and spectrum of linezolid and only
the six most effective comparison drugs are shown
in Table 3 for vancomycin-susceptible E. faecium.
Based on these 262 isolates, linezolid susceptibility
was 90.5 (disk diffusion) to 96.8% (broth micro-
dilution) and no conﬁrmed resistant strains were
detected. Similarly, teicoplaninwas active (suscep-
tible or intermediate) against all strains, and
quinupristin/dalfopristin was only moderately
effective in vitro, with a susceptibility rate of only
60.3–84.4%, depending on the susceptibility
method used. Numerous streptogramin non-sus-
ceptible E. faecium isolates were conﬁrmed by the
monitors as being the correct species identiﬁcation
[32] and MIC result (generally an MIC of 2mg/L;
intermediate). These quinupristin/dalfopristin
non-susceptible strains were identiﬁed in eight
countries including Austria (two strains, 11.1%),
Belgium (10 strains, 52.7%), France (15 strains,
34.1%), Iceland (one strain, 16.7%), Italy (ﬁve
strains, 50.0%), The Netherlands (three strains,
20.0%), Spain (17 strains, 31.3%) and Switzerland
(three strains, 16.7%). Among the remaining tested
antimicrobials, the rank order of susceptibility
was: chloramphenicol (73.9–77.9%) > doxycycline
> trovaﬂoxacin > ampicillin (32.2–41.3%).
Table 4 lists the in vitro spectrum and potency of
the same seven agents shown in Table 3 when
tested against vancomycin-susceptible E. faecalis.
Table 1 Antimicrobial activity of linezolid and 12 other compounds tested against 1950 S. aureus strains categorized by
oxacillin susceptibility
Oxacillin-susceptible Oxacillin-resistant
% susceptible/resistant % susceptible/resistant
Antimicrobial
agent
MIC90a
(mg/L)
Median
zone (mm)b
BMDa
(n¼ 262)
Diskb
(n¼ 997)
MIC90a
(mg/L)
Median
zone (mm)b
BMDa
(n¼ 140)
Diskb
(n¼ 551)
Linezolid 2 29 100.0 100.0 2 28 100.0 100.0
Vancomycin 1 18 100.0 99.8 1 19 100.0 99.6
Teicoplanin 0.5 17 100.0 98.2 2 17 100.0 95.8
Quinupristin/
Dalfopristin
0.5 25 99.6 99.9 0.5 25 98.6 99.6
Erythromycin >16 26 68.3 85.5 >16 6 12.9 17.2
Clindamycin >16 26 84.3 95.2 >16 6 17.9 42.1
Chloramphenicol 8 24 96.9 98.2 8 23 94.3 91.8
Doxycycline 4 28 98.1 94.6 8 27 85.7 83.3
Ampicillin >16 ND 13.0 NDc >16 ND 0.0 ND
Cefazolin 0.5 28 98.9 99.7 >16 6 0.0 0.0
Ceftriaxone ND 26 ND 96.1 ND 6 ND 0.0
Cefotaxime 2 ND 99.2 ND >32 ND 0.0 ND
Trovafloxacin 0.5 32 99.6 98.9 >8 20 59.3 81.5
aReference broth microdilution method [29] and interpretative susceptibility criteria of the NCCLS [27]. The product
package insert criteria were applied to trovafloxacin (2mg/L).
bStandardized disk diffusion method [28]and interpretative susceptibility criteria of the NCCLS [27]. The product package
insert criteria were applied to trovafloxacin (17mm).
c
ND¼not determined by that method.
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No linezolid-resistant strains were identiﬁed and
conﬁrmed. All linezolid in vitro testing results
were within the susceptible (95.1–97.1%) or inter-
mediate (2.9–4.9%) categories. Although teicopla-
nin zone diameters were occasionally noted in the
intermediate category (1.2%), no resistant strains
were conﬁrmed. Consistent with numerous
reports characterizing the quinupristin/dalfopris-
tin spectrum, this drug was not active (MIC90,
>16mg/L; median zone diameter, 12mm) against
E. faecalis [6,32]; and resistance among susceptible
E. faecium has been reported to emerge on pro-
longed therapeutic regimens [33]. Ampicillin
remains very potent (MIC90, 1mg/L; median zone
diameter, 26mm) against this enterococcal species,
but the other agents were less likely to achieve a
usable spectrum (% susceptible range, 39.2–
87.9%).
Table 2 Antimicrobial activity of linezolid and 12 other compounds tested against 1353 coagulase-negative Staphylococcus
spp. (CoNS) strains categorized by oxacillin susceptibility
Oxacillin-susceptible Oxacillin-resistant
% susceptible/resistant % susceptible/resistant
Antimicrobial
agent
MIC90a
(mg/L)
Median
zone (mm)b
BMDa
(n¼ 102)
Diskb
(n¼ 415)
MIC90a
(mg/L)
Median
zone (mm)b
BMDa
(n¼ 182)
Diskb
(n¼ 654)
Linezolid 2 32 100.0 100.0 2 33 100.0 100.0
Vancomycin 2 21 100.0 100.0 2 20 100.0 99.7
Teicoplanin 2 18 100.0 94.7 4 17 97.8 93.2
Quinupristin/
Dalfopristin
0.25 29 100.0 99.8 0.5 29 96.2 99.8
Erythromycin >16 28 70.6 67.5 >16 6 33.3 27.9
Clindamycin 0.5 28 93.1 89.4 >16 25 56.8 57.8
Chloramphenicol 8 27 98.0 96.9 >16 25 84.7 81.8
Doxycycline 4 29 94.1 86.5 8 26 88.0 80.6
Ampicillin 2 ND 49.0 NDc >16 ND 0.0 ND
Cefazolin 0.25 35 100.0 99.3 >16 24 0.0 0.0
Ceftriaxone ND 30 ND 94.9 ND 15 ND 0.0
Cefotaxime 1 ND 100.0 ND >32 ND 0.0 ND
Trovafloxacin 0.12 33 99.0 97.1 8 24 63.4 84.6
aReference broth microdilution method [29] and interpretative susceptibility criteria of the NCCLS [27]. The product
package insert criteria were applied to trovafloxacin (2mg/L).
bStandardized disk diffusion method [28] and interpretative susceptibility criteria of the NCCLS [27]. The product package
insert criteria were applied to trovafloxacin (17mm).
c
ND¼not determined by that method.
Table 3 Antimicrobial activity of linezolid and five other compounds tested against 262 vancomycin-susceptible E. faecium
strainsa
Antimicrobial agent MIC90
b
Median
zone (mm)c
BMDb
(n¼ 63)
Diskc
(n¼ 199)
Linezolid 2 27 96.8d 90.5d
Teicoplanin 0.5 19 100.0 99.0e
Quinupristin/Dalfopristin 4 22 60.3 84.4
Chloramphenicol 16 21 77.8 73.9
Doxycycline >8 23 41.3 64.3
Ampicillin >16 6 41.3 32.2
Trovafloxacin >8 15 46.0 46.2
aThere were only nine vancomycin-resistant strains. Two of these strains were van A (data not shown).
bReference broth microdilution method [27] with trovafloxacin breakpoint at 2mg/L.
cNCCLS [28] disk diffusion method and criteria with trovafloxacin breakpoints taken from the product package insert.
dNo linezolid-resistant strains were noted.
eNo teicoplanin-resistant strains were observed.
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A total of 16 conﬁrmed vancomycin-resistant
enterococci were identiﬁed in the participating
European centers during this trial. These strains
were: E. faecium (nine strains), E. faecalis (four
strains) and Enterococcus spp., (three strains).
The E. faecalis isolates were all of the van B resis-
tance phenotype, isolated in Austria (one strain)
and Italy (three strains). The E. faecium VRE iso-
lates were van B (seven strains) and van A (two
strains) phenotypes discovered in Austria (two
strains) and the UK (seven strains). The remaining
unspeciated VRE were single isolates (one van B,
two van A) detected in Germany, Ireland and the
UK. The rates of VRE among all strains sampled in
this trial by nation was UK (5.9%) > Italy (3.9%) >
Austria (3.0%)> Ireland (2.5%)>Germany (0.7%).
The other eight nations did not report the isolation
of VRE strains.
The most active agents against these European
isolates (16 strains) of VRE were: linezolid
(100.0%) > teicoplanin (75.0%) > chloramphenicol
¼ doxycycline (68.8%) > quinupristin/dalfopris-
tin (62.5%) > ampicillin (43.8%) > trovaﬂoxacin
(25.0%).
Linezolid tested against streptococci
The results of testing linezolid and ﬁve other
agents by the E test (AB BIODISK) method against
S. pneumoniae strains are found in Table 5. The
organisms were subdivided by their susceptibility
categories to penicillin, 25.1% of strains being non-
susceptible (4.9% high-level resistance at MICs of
2mg/L). Linezolid activity (MIC90, 0.75–1mg/L)
was not affected by the penicillin-resistance pat-
terns (100.0% susceptible). Similarly, no changes in
the quinupristin/dalfopristin (MIC90, 0.75–1mg/
L) or trovaﬂoxacin (MIC90, 0.19mg/L) potency
was noted. In contrast, other b-lactams (ceftriax-
one) and the macrolide demonstrated increasing
MIC50 and MIC90 results as the penicillin MIC
increased. The spectrum of erythromycin also
decreased from 92.4% among penicillin-suscepti-
ble strains to only 29.4% for the penicillin-resistant
pneumococci. Although the MIC90 for ceftriaxone
increased from 0.023 to 0.75mg/L (32-fold
change), the spectrum only diminished from
100.0 to 97.1%.
Quinupristin/dalfopristin-resistant strainswere
detected at a greater frequency among penicillin-
resistant strains (2.9%), with these strains isolated
in Denmark (one strain), France (one strain), Ger-
many (one strain) and Spain (two strains). The
non-susceptible MIC results, however, only ran-
ged from 1.5 to 4mg/L.
The E test results of the remaining 174 Strepto-
coccus spp. isolates are found in Table 6. Linezolid
potency (MIC90, 1mg/L) and spectrum (100.0%)
against the viridans group and b-haemolytic strep-
tococci was identical to that observed for the
pneumococci (Table 5). Quinupristin/dalfopristin
and trovaﬂoxacin also were 100.0% effective with
MICs at or below the applied breakpoint concen-
tration [27,31]. Penicillin (MIC90, 0.094mg/L) and
ceftriaxone (MIC90, 0.094mg/L) were very active
and only 1.1% of strains were categorized as resis-
tant. Only erythromycin (MIC90, 2mg/L) had a
compromised spectrum.
Table 4 Antimicrobial activity of linezolid and five other compounds tested against 815 vancomycin-susceptible E. faecalis
strains categorized by vancomycin susceptibilitya
Antimicrobial
agent
MIC90
b
(mg/L)
Median
zone (mm)c
BMDb
(n¼ 240)
Diskc
(n¼ 575)
Linezolid 2 27 97.1d 95.1d
Teicoplanin 0.5 19 100.0 98.8e
Quinupristin/Dalfopristin >16 12 2.9 5.7
Chloramphenicol >16 20 60.4 72.9
Doxycycline >8 15 39.2 48.9
Ampicillin 1 26 100.0 97.4
Trovafloxacin 4 23 87.9 73.2
aFour strains were vancomycin-resistant (van B pattern).
bReference broth microdilution method [29] a with trovafloxacin breakpoint at 2mg/L.
cNCCLS [28] disk diffusion method and criteria with trovafloxacin breakpoints (17mm) taken from the product package
insert.
dNo linezolid-resistant strains were detected.
eNo teicoplanin-resistant strains were observed.
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DISCUSSION
This surveillance has generated a large, controlled
European database on the susceptibility of 5598
clinically relevant Gram-positive pathogens. The
strains were from 41 centers distributed through-
out 13 countries from the north to the south of
Europe. Susceptibility testing has been performed
with deﬁned, common lot reagents provided to
each participant. Also, since the results have been
scrutinized for quality compliance, the data can be
reliably pooled and analysed to provide crucial
information on the trends of emerging resistances
such as VRE, GISA, DRSP and the comparative
spectrum and potency of established or newer
Gram-positive spectrum antimicrobials. As pre-
viously reported [23,34], vancomycin resistance
in enterococci remains very low at 0.6% for E.
faecalis and 3.0% for E. faecium on the European
continent compared tomore than 50% for the latter
species reported in North America [23]. For S.
pneumoniae, the level of penicillin resistance (inter-
mediate and resistant) of 25% in Europe was
similar to that described in the United States
(29.7%), while the high-level penicillin resistance
(MIC, 2mg/L) was three-fold higher in the Uni-
ted States (13 vs. 5%). Although there were spora-
dic reports of GISA in this study, these were all
artefacts associated with disk diffusion testing and
were not conﬁrmed upon repeat testing at the
monitor sites using reference methods and the
so-called E test macromethod [35]. While labora-
tories in North America have been warned of the
limitations of disk diffusion testing with vanco-
mycin against staphylococci [24,36], it appears that
European centers may not be similarly informed.
As in the outcomes reported in the United
States ZAPS surveillance [17], linezolid was
Table 5 Antimicrobial activity of linezolid and four other antimicrobial agents tested against 699 S. pneumoniae strains
categorized by penicillin susceptibilitya
Antimicrobial agent
Penicillin
categorya
(no. tested)
MIC (mg/L)b % by categoryc
50% 90% Susceptible Resistant
Linezolid S (n¼ 524) 0.5 1.0 100.0 –
I (n¼ 141) 0.5 0.75 100.0 –
R (n¼ 34) 0.5 1.0 100.0 –
Quinupristin/Dalfopristin S (n¼ 524) 0.5 0.75 99.6 0.2
I (n¼ 141) 0.5 1.0 99.3 0.7
R (n¼ 34) 0.5 1.0 91.2 2.9
Erythromycin S (n¼ 524) 0.094 0.25 92.4 6.6
I (n¼ 141) 3.0 >256 44.7 54.6
R (n¼ 34) >256 >256 29.4 70.6
Ceftriaxone S (n¼ 524) 0.008 0.023 100.0 0.0
I (n¼ 141) 0.19 0.5 99.3 0.7
R (n¼ 34) 0.5 0.75 97.1 2.9
Trovafloxacin S (n¼ 524) 0.094 0.19 100.0 0.0
I (n¼ 141) 0.094 0.19 100.0 0.0
R (n¼ 34) 0.094 0.19 100.0 0.0
aPenicillin-susceptible (S) at 0.06mg/mL; intermediate (I) at 0.12–1mg/L and resistance (R) at 2mg/L [27].
bTesting performed using E test (AB BIODISK) method.
cNCCLS [27] interpretative criteria used for breakpoints. No intermediate or resistant criteria have been defined for
linezolid.
Table 6 Antimicrobial activity of linezolid and five other
antimicrobial agents tested by E test (AB BIODISK) against
174 other Streptococcus spp. strains
Antimicrobial agent
MIC (mg/L) %by categorya
50% 90% Susc. Res.
Linezolid 0.75 1.0 100.0 0.0
Quinupristin/
Dalfopristin
0.38 0.5 98.3 0.0
Penicillin 0.016 0.094 96.0 1.1
Erythromycin 0.125 2.0 81.6 14.4
Ceftriaxone 0.023 0.094 98.3 1.1
Trovafloxacin 0.094 0.25 100.0 0.0
aInterpretive criteria used those published by the NCCLS
[27] for the viridans group streptococci; Susc., susceptible;
Res., resistant.
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all-encompassing in its spectrumof activity against
the Gram-positive cocci tested, where unimodal
distributions of MIC values or zone sizes were
documented with no skewing to suggest the pre-
sence or emergence of strains with reduced
susceptibility. For streptococci, including S. pneu-
moniae, E test MICs showed a homogeneously
susceptible population across the 0.25–2mg/L
MIC range regardless of the penicillin- or macro-
lide-resistance phenotype. While the potency of
erythromycin was severely compromised (29.4%
susceptible in penicillin-resistant isolates), the
other tested agents remain useful therapeutic
options.
For enterococci, susceptibility to linezolid
remains very high even against the small number
of VRE phenotypes. However, a slight reduction in
susceptibility (intermediate category by NCCLS
criteria) [27] was noted, although none of these
strains were conﬁrmed to be linezolid-resistant
(MIC, 8mg/L). Even among the enterococci,
the disk diffusion results seem to reﬂect a higher
occurrence of reduced linezolid susceptibility,
potentially a laboratory artefact due to problems
in reading the zone at 80% inhibition, as is normal
for several bacteriostatic drugs. The margin
between the breakpoint and the distribution of
oxazolidinone-susceptible MIC values does not
provide a full log2 dilution to accommodate test-
ing variations. Thus, the tail of the normal MIC
distribution curve may be intersected and this can
generate ‘false-intermediate’ and rarely ‘false-
resistant’ results. Such problems of susceptibility
testing interpretation would not be encountered
with the EUCAST criteria [31]. Even the current
NCCLS QC ranges (1–4mg/L) for linezolid when
using either S. aureus ATCC 29213 or E. faecalis
ATCC 21212 indicate the potential for organisms
to produce results in the non-susceptible category
(MIC at 4mg/L). Accurate susceptibility testing of
linezolid remains very important to recognize the
very rare event of resistance emerging on extended
therapy that has been reported among E. faecium
[37] and S. aureus [38].
While ampicillin and teicoplanin remain highly
active against essentially all E faecalis, linezolid
appears to be the rational empiric option for E
faecium infections considering the emergence and
prevalence of the van A phenotype compromising
the activity of teicoplanin, and the modest level of
susceptibility (60.3–84.4%; Table 3) for quinupris-
tin/dalfopristin. Also the linezolid activity against
staphylococci was outstanding (100% susceptibil-
ity) regardless of the resistance phenotype – oxa-
cillin, macrolide, lincosamide, or quinolone
resistance. With glycopeptide resistance being a
growing concern [24,36], the availability of line-
zolid combined with its favourable pharmacoki-
netics makes this oxazolidinone a strong candidate
as a drug of choice in the treatment of serious
staphylococcal infections.
The ZAPS international surveillance initiative
has provided a valuable baseline with which post-
marketing studies along similar study designs can
continue to generate meaningful susceptibility
information [17]. This is necessary to monitor for
the earliest possible signals of resistance to the
oxazolidinone compounds [37,38] and to enable
other dosage regimens to be developed based on
MIC-PK/PD models. These results conﬁrm other
less comprehensive national surveillance data in
Europe [16,18,39] and support the data reported
from the Americas [17].
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